For the fourth year in a row, cancer is the top condition driving health care cost, which is growing at an astounding rate
Faced with this global health challenge, glucagon-like peptide-1 receptor agonists (GLP-1RAs) have garnered significant attention for their dual effects in glucose control and weight reduction
The Three Generations of Incretin Peptide Research The progression from single to dual to triple agonist peptides represents a research trajectory that has played out in roughly ten years: Generation 1 Single GLP-1 Agonists (Semaglutide, Liraglutide, Exenatide) The first incretin peptides to reach broad clinical research were GLP-1 receptor agonists
Early Parkinsons and Huntingtons studies remain mixed but suggest disease-modifying potential
See our how to get retatrutide guide for the full FDA timeline, clinical trial enrollment steps, and what alternatives are available now
Why GLP-1 Non-Responders Need Earlier Anti-Obesity Medication Intervention Introduction GLP-1 non-responders represent a critical challenge in obesity management that requires prompt medical intervention
